ArticleADMET & DMPK2025
TiO
Article in ADMET & DMPK, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: The precise quantification and quality evaluation of glycopyrronium bromide (GLB), a long-acting muscarinic antagonist widely used in the treatment of chronic obstructive pulmonary disease, requires the development of advanced analytical methodologies capable of achieving high sensitivity, accuracy, and selectivity to ensure therapeutic efficacy and formulation integrity. This study aims to overcome the limitations of conventional methods by developing a rapid, cost-effective method for determining GLB. Experimental approach: To achieve this, titanium dioxide nanoparticles (TiO Key results: The optimized GLB/4-ABA@TiO Conclusion: The designed nanomaterial-embedded MIP-based electrochemical system presented here offers a highly successful, sensitive, and selective method for GLB determination. The work significantly advances knowledge in the field of analytical medicine and drug monitoring by providing a fast, robust alternative for routine clinical and quality-control tracking of GLB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.